Gunderson Dettmer represented microfluidics client Miroculus in its acquisition by INTEGRA Biosciences, a medical equipment manufacturer. Miroculus simplifies complicated next generation sequencing (NGS) protocols and empowers researchers to translate their discoveries into practical solutions that are accessible to all. The acquisition will enable INTEGRA to extend its reach in the growing NGS market, offering novel process automation solutions to help academic, research and diagnostics laboratories save time and accelerate discovery.

In the announcement of the acquisition, founder and CEO of Miroculus Alejandro Tocigl said, “We began Miroculus with the mission to advance science and improve lives faster, and the last year has been very eventful for us as we’ve worked to achieve this goal. Most notably, we launched the Miro Canvas™ system, a revolutionary digital microfluidics platform that fully automates NGS sample preparation protocols. We are extremely excited that the Miroculus team will now be a part of the INTEGRA group, and this acquisition will continue our shared culture of innovation for the scientific community.”

The Gunderson Dettmer deal team was led by corporate partner Dan Green, M&A partner John Olson, and corporate associate Nate Gray, and included tech/IP partner Colin Chapman, executive compensation partner Michael Richman, employment & labor partner Natalie Pierce, tax/fund partner Lily Kim, of counsel Michael Hui, and associates Micaela Cervantes, Sungha Park, Cameron Jahansouz, Alice Lu, Shagun Parekh, Andrew Leeds, and Tina Xu.

Companies
Miroculus
INTEGRA Biosciences